Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ALG-801
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AliveGen Completes Phase 1b Trial for ALG-801 Multiple Dosing
Details : BIIB110 (ALG-801) is a next-gen ligand trap that selectively sequesters TGF-beta family members. It's evaluated for muscle wasting, metabolic disorders, and neuromuscular diseases.
Brand Name : BIIB110
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 18, 2024
Lead Product(s) : ALG-801
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?